2:08 Mitochondrial Metabolism Inhibitors as a CML Treatment? CML Content Hub @VignirHelgason, of @UofGlasgow, discusses #mitochondrial #metabolic #inhibitors for #CML.
1:41 Risk Stratifying CML Patients for Cardiovascular Adverse Events When Choosing First-Line Therapy CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #risk stratification and #TKI selection in #CML.
1:53 5-Year Results Solidify Bosutinib’s Increased Efficacy vs Imatinib CML Content Hub @GCC_Cortes of @GACancerCenter discusses #bosutinib in #CML.
2:28 Optimizing CML Treatment: Latest Clinical Trial Data on TKI Efficacy and Dosage CML Content Hub @CoplandMhairi, of @UofGlasgow, discusses #TKI efficacy and #dosage.
13:25 An Overview of Research Program for Pompe Disease Pompe Disease Content Hub Priya Kishnani, MD, of @DukeMedSchool, discusses #translational #research on #PompeDisease.
1:37:47 Small Molecule Inhibitor Reduces Glycogen in Preclinical Mouse Models of Pompe Disease Pompe Disease Content Hub Julie Ullman, PhD, of @MazeInBiotech, discusses #preclinical #results on #MZE001 for #PompeDisease.
2:10 Multidisciplinary Approach to Managing Pompe Disease Pompe Disease Content Hub Priya Kishnani, MD, of @DukeMedSchool, discusses #multidisciplinary care for #PompeDisease.
54:32 Newborn Screening for Pompe Disease Pompe Disease Content Hub Damara Ortiz, MD, of @ChildrensPgh, discusses #screening for #PompeDisease.
1:31:53 CML Management and Emerging Therapies CML Content Hub Ehab Atallah, MD, of @MedicalCollege, and @mjmauroMD, of @MSKCancerCenter, discuss #emerging #therapies for #CML.
5:42 Highlights From CICON22 Day 4 Oncology Benjamin Vincent, MD, of @UNCLineberger, provides #immunotherapy highlights from #CICON22.
3:34 Contribution of Air Pollution to Lung Cancer Development Oncology @CharlesSwanton of @TheCrick discusses how #air #pollution causes #lung #cancer.
28:43 Viral Therapy & Immunotherapy Allergy / Immunology Rimas Lukas, MD, @NorthwesternMed, @NMNeurology, @BrainTumorInst, discusses #viral #therapy for #glioblastoma.
